Several trials have demonstrated that combining tepotinib and osimertinib could potentially overcome resistance caused by MET amplification and lead to a significant improvement in the objective remission rate for patients with MET‐amplified NSCLC.260, 261. Here, MET is linked to non-small cell lung carcinoma.